DNA Ginkgo Bioworks
Ginkgo Bioworks earnings company data as of 6:52 PM ET 10/23
Limited consensus data for this ticker (thin coverage or data-plan limits).
Dates may be company-announced rather than sell-side consensus.
Calendar and recent prints remain the primary lens when available.
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 5 Nov | EPS | — | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by DNA's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- $35K sold by 1 insider outside a trading plan
- $36K sold by 1 insider under 10b5-1 plans
-
Steven P. Coen See remarksPlanned sale$36K 2,403 shares at $15.00 4.6% of stakeTraded Oct 5 Filed Oct 7
-
Christian O Henry DirectorSale$35K 5,000 shares at $7.08 21% of stakeTraded Sep 15 Filed Sep 16
Also filed in the last 12 months, not counted as buying or selling: 37 option exercises and 22 sales to cover taxes.
SEC filings
Recent issuer filings from EDGAR, 16 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc | |
| 8-K | 5.07 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| 8-K | 2.01,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 1.01,9.01 | Filing Doc | |
| 8-K | 2.02 | Filing Doc | |
| 10-K | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.